Optibiotix Health: Funding, Investors & Team (Sep 2026)
OptiBiotix develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Optibiotix Health has raised $2.8M across 2 funding rounds on record, the most recent an undisclosed round of $1.0M announced in May 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Optibiotix Health Company Profile and Key Stats
Latest funding round on record: May 2025.
Optibiotix Health Funding Rounds
Optibiotix Health raised $1.8M in an undisclosed round announced in Mar 2024.
1.2 years later, an undisclosed round of $1.0M was announced in May 2025.
Optibiotix Health Founders and Leadership Team
No contact details are on record for this team yet.
Optibiotix Health Funding Compared to Other Biotechnology Startups
Optibiotix Health's latest round of $1.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Optibiotix Health in Biotechnology and Heslington
Companies Similar to Optibiotix Health
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Optibiotix Health Funding FAQs
What does Optibiotix Health do?
OptiBiotix develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
How much funding has Optibiotix Health raised?
Optibiotix Health has raised $2.8M across 2 rounds on record. The most recent is an undisclosed round of $1.0M announced in May 2025.
When did Optibiotix Health last raise funding?
Optibiotix Health's most recent funding round on record is an undisclosed round of $1.0M, announced in May 2025.
Who founded Optibiotix Health?
FundedIQ lists Stephen O' Hara (Founder) at Optibiotix Health.
Where is Optibiotix Health headquartered?
Optibiotix Health is based in Heslington, York, United Kingdom.
How many employees does Optibiotix Health have?
Optibiotix Health is in the 11-50 employee band.
How does Optibiotix Health's funding compare to other Biotechnology startups?
Optibiotix Health's latest round of $1.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Optibiotix Health Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Optibiotix Health is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.